Search Details

Word: bristols (lookup in dictionary) (lookup stats)
Dates: during 1990-1999
Sort By: most recent first (reverse)


Usage:

Last week a report from Bristol-Myers Squibb, the manufacturers of DDI, suggested that the skeptics may have been right. The report disclosed that of 8,000 patients who had been taking DDI for seven months under the FDA's "expanded access" program, 290 died. That was ten times the death rate found in Bristol-Myers' own controlled clinical trial, in which 700 patients have received DDI. The report raised concerns not only about the safety of the drug but also about the FDA's new liberalization program...

Author: /time Magazine | Title: Medicine: Case of The Unexplained Deaths | 3/26/1990 | See Source »

...clinic offering the drug to AIDS sufferers in New York City. Dr. Anthony Fauci of the National Institutes of Health observes that the death rate was much lower than that found in the early trials of AZT. But the report does raise "a red flag," adds Fauci, obliging either Bristol-Myers or the Government to investigate the affair...

Author: /time Magazine | Title: Medicine: Case of The Unexplained Deaths | 3/26/1990 | See Source »

Major pharmaceutical firms like Merck & Co. of Rahway, N.J., and Bristol- Myers Squibb of New York City are keeping a low profile in the pricing debate. The corporate rebuttal is that drug firms are honestly struggling to contain their spiraling costs and turn a profit in a formidably complex and competitive industry. Research and development costs, the key to corporate success in the drug industry, have lofted from an average of $55 million for each new medication in the 1970s to $125 million today. Regulatory agencies like the U.S. Food and Drug Administration can take up to seven years...

Author: /time Magazine | Title: The Price Isn't Right | 1/8/1990 | See Source »

...market. Although the global industry has always boasted its share of non-U.S. giants, such as Switzerland's Ciba-Geigy and West Germany's Bayer AG, American firms average 40% of their sales outside the country. This year's three biggest drug-company mergers all involved U.S. companies. Bristol-Myers (1988 sales: $6 billion) joined Squibb of Princeton, N.J. ($2.6 billion); Philadelphia's SmithKline Beckman ($3 billion) merged with Britain's Beecham ($3 billion); Merrell Dow ($1.3 billion) of Midland, Mich., merged with Marion Labs ($752 million) of Kansas City. "Pharmaceuticals is the one industry in which...

Author: /time Magazine | Title: The Price Isn't Right | 1/8/1990 | See Source »

Previous | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | Next